While valuations across the pharmaceutical industry have soared this year -- with shares of diversified giants like Merck (MRK 0.15%) and Pfizer up significantly -- Bristol-Myers Squibb (BMY -0.64%) in particular has been on a tear recently. In the last 12 months, its shares are up a whopping 40%. However, despite all of the promising drugs that the company is developing in clinical trials, is there any upside left in this stock today? In the following video, analysts David Williamson and Max Macaluso discuss three reasons to consider selling Bristol-Myers.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
3 Reasons to Sell Bristol-Myers Squibb
NYSE: BMY
Bristol Myers Squibb

Are there any reasons to sell one of the best performing pharmaceutical stocks of the year?
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned




*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.